Journal Article

METRIC (MREnterography or ulTRasound in Crohn’s disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in those aged 16 and over

Taylor, Stuart, Punwani, Shonit, Travis, Simon, Higginson, Antony, Gupta, Arun, Rodriguez-Justo, Manuel, Windsor, Alastair, Slater, Andrew, Halligan, Steve, Murray, Charles, Wylie, Peter, McCartney, Sara, Bloom, Stuart, Tolan, Damian, Zealley, Ian, Jacobs, Ilan, Hart, Ailsa, Muirhead, Nicola, Hamlin, John, Morris, Steve, Mallett, Susan, Bhatnagar, Gauraang

2014

Overview

Background Crohn’s disease (CD) is a lifelong, relapsing and remitting inflammatory condition of the intestine. Medical imaging is crucial for diagnosis, phenotyping, activity assessment and detecting complications. Diverse small bowel imaging tests are available but a standard algorithm for deployment is lacking. Many hospitals employ tests that impart ionising radiation, of particular concern to this young patient population. Magnetic resonance enterography (MRE) and small bowel ultrasound (USS) are attractive options, as they do not use ionising radiation. However, their comparative diagnostic accuracy has not been compared in large head to head trials. METRIC aims to compare the diagnostic efficacy, therapeutic impact and cost effectiveness of MRE and USS in newly diagnosed and relapsing CD. Methods METRIC (ISRCTN03982913) is a multicentre, non-randomised, single-arm, prospective comparison study. Two patient cohorts will be recruited; those newly diagnosed with CD, and those with suspected relapse. Both will undergo MRE and USS in addition to other imaging tests performed as part of clinical care. Strict blinding protocols will be enforced for those interpreting MRE and USS. The Harvey Bradshaw index, C-reactive protein and faecal calprotectin will be collected at recruitment and 3 months, and patient experience will be assessed via questionnaires. A multidisciplinary consensus panel will assess all available clinical and imaging data up to 6 months after recruitment of each patient and will define the standard of reference for the presence, localisation and activity of disease against which the diagnostic accuracy of MRE and USS will be judged. Diagnostic impact of MRE and USS will be evaluated and cost effectiveness will be assessed. The primary outcome measure is the difference in per patient sensitivity between MRE and USS for the correct identification and localisation of small bowel CD. Discussion The trial is open at 5 centres with 46 patients recruited. We highlight the importance of stringent blinding protocols in order to delineate the true diagnostic accuracy of both imaging tests and discuss the difficulties of diagnostic accuracy studies in the absence of a single standard of reference, describing our approach utilising a consensus panel whilst minimising incorporation bias. Trial registration METRIC - ISRCTN03982913 – 05.11.13.

• Publisher: BioMed Central,Springer Nature B.V
• Subject: Adolescent / Adult / Aged / Cohort Studies / Cost-Benefit Analysis / Crohn Disease - diagnosis / Crohn Disease - diagnostic imaging / Crohn Disease - pathology / Gastroenterology / Hepatology / Humans / Internal Medicine / Intestinal disorders / Intestine, Small - diagnostic imaging / Intestine, Small - pathology / Magnetic Resonance Imaging - economics / Medicine / Medicine & Public Health / Middle Aged / Prospective Studies / Recurrence / Study Protocol / Ultrasonography - economics / Young Adult